2023 North America Conference on Lung Cancer (NACLC) - Posters and Abstracts-PP01.02 (Poster) Clinical characteristics and outcomes of patients with EGFR mutated non-small cell lung cancer treated by EGFR targeted therapy then immunotherapy

PP01.02 (Poster) Clinical characteristics and outcomes of patients with EGFR mutated non-small cell lung cancer treated by EGFR targeted therapy then immunotherapy

Back to course

Pdf Summary

A study conducted at Mayo Clinic aimed to evaluate the clinical outcomes of patients with EGFR-mutated non-small cell lung cancer (NSCLC) who were treated with an EGFR-tyrosine kinase inhibitor (TKI) followed by immunotherapy (IO). The study included 59 patients with EGFR mutations who were treated between January 2014 and December 2022. Patient characteristics, EGFR mutation status, and clinical outcomes were collected and analyzed.<br /><br />The results showed that patients treated with IO monotherapy after progressing on EGFR TKI did not exhibit a durable treatment response compared to those receiving combination chemoimmunotherapy. This suggests a benefit from cytotoxic agents in this clinical context. Additionally, patients with non-classical EGFR mutations may have improved outcomes with immunotherapy.<br /><br />The median overall survival (OS) for the entire cohort was 41 months, and the median progression-free survival (PFS) on initial EGFR therapy was 13 months. Patients who received a second EGFR TKI had increased median OS of 70 months compared to 29 months in patients who did not receive a second TKI. The median PFS on patients who received a second EGFR TKI was 29 months. The median PFS on IO therapy with or without chemotherapy was 5 months, with a median duration of treatment of 4 months.<br /><br />The study highlights the importance of considering combination chemoimmunotherapy in patients with EGFR-mutated NSCLC who have progressed on EGFR TKI therapy. It also suggests that further research is needed to explore treatment options for EGFR therapy resistance. The findings provide valuable insights for clinicians in selecting therapeutics for patients with EGFR-mutated NSCLC.

Asset Subtitle

Antonious Hazim

Keywords

EGFR-mutated non-small cell lung cancer

EGFR-tyrosine kinase inhibitor

immunotherapy

clinical outcomes

cytotoxic agents

chemoimmunotherapy

non-classical EGFR mutations

overall survival

progression-free survival

EGFR therapy resistance